Americans Are About to Lose Access to Cheap Gray-Market Prescriptions From Canada

 

Americans Are About to Lose Access to Cheap Gray-Market Prescriptions From Canada

For years, some Americans have relied on Canadian and other foreign pharmacies when the price of a prescription in the United States was simply too high.

The arrangement has occupied an unusual space in the American health-care system. It has not generally been the same as buying medicine through the conventional U.S. supply chain, and federal law places significant restrictions on importing prescription drugs. Yet regulators have historically exercised enforcement discretion in some circumstances, allowing individual patients to receive medicines from abroad.

That arrangement is now facing a major change.

New U.S. customs requirements scheduled to take effect October 22, 2026, are expected to make many international mail-order prescription shipments substantially more difficult to process. The Canadian International Pharmacy Association says the changes could interrupt the system used by many Americans to receive medicines from Canadian and other foreign pharmacies. 

P

Pharmacie Internationale Canadienne

For patients who have depended on those lower prices, the issue is not abstract. It can mean the difference between being able to afford a medicine and going without it.

A workaround built around a price gap

The appeal of Canadian pharmacies is straightforward: some prescription medicines can cost substantially less outside the United States.

One patient profiled in recent reporting, Diamantina Cavazos of Texas, has been paying roughly $10 a week for Xifaxan through a Canadian online pharmacy. The comparable U.S. cost she faces without adequate insurance coverage could be dramatically higher. 

D

Democratic Underground

+1

Stories like hers illustrate why cross-border drug purchasing has persisted despite the complicated legal environment.

For people with chronic conditions, the difference isn't necessarily about getting a bargain on an occasional purchase. It can determine whether a treatment remains financially sustainable month after month.

Why the system is changing

The coming change involves the way international mail containing goods subject to additional government requirements is processed by U.S. Customs.

The Canadian International Pharmacy Association says the new requirements will create compliance obligations that many existing personal prescription shipments cannot realistically meet, potentially disrupting deliveries beginning October 22. 

P

Pharmacie Internationale Canadienne

That does not mean every prescription coming from Canada will automatically become illegal or that every patient will lose access to every foreign-sourced medicine.

Rather, the concern is that the established mail-order model used by individual consumers may no longer be practical at scale.

The FDA's position is more complicated

The FDA has long warned Americans about purchasing prescription medicines from foreign or unfamiliar online pharmacies.

The agency says drugs outside the legitimate U.S. supply chain may not have the same guarantees concerning safety, effectiveness, manufacturing quality, labeling and storage. It specifically warns that some unsafe online pharmacies sell counterfeit or otherwise inappropriate medicines. 

U

U.S. Food and Drug Administration

+1

Under federal law, importing an unapproved drug is generally prohibited. The FDA nevertheless recognizes that there are circumstances in which individuals may seek to import medicines for personal use, and it has criteria governing when such situations may receive consideration. The agency emphasizes that personal-importation policies do not create an individual legal right to import an unapproved medicine. 

U

U.S. Food and Drug Administration

That distinction is important.

The existence of enforcement discretion should not be confused with a blanket authorization for Americans to order prescription drugs from abroad.

At the same time, the government wants cheaper drugs

There is an apparent contradiction at the heart of the debate.

The federal government is simultaneously tightening controls around some foreign prescription shipments while expanding formal pathways intended to make imported medicines cheaper.

The FDA operates a Section 804 Importation Program that allows states and certain other entities to seek authorization to import qualifying prescription drugs from Canada. The program is designed to reduce costs while maintaining safeguards around drug quality and safety. 

U

U.S. Food and Drug Administration

+1

In March 2026, the FDA said it had met with states interested in the program as part of efforts to make Canadian drug importation easier to implement. 

U

U.S. Food and Drug Administration

But there is an important difference between an authorized state importation program and an individual consumer ordering medicine from an overseas pharmacy.

The former operates within a regulatory framework involving government oversight, approved products and specified supply-chain requirements.

The latter exists in a much more uncertain space.

The affordability dilemma

That leaves patients facing a difficult reality.

The government can argue that medicines entering the country need to meet appropriate safety and regulatory standards. Patients can simultaneously point to enormous differences between American drug prices and what they may pay elsewhere.

Both facts can exist at once.

For someone whose insurance covers a medicine, the difference in list prices may matter little. For someone facing a high deductible, an uncovered drug or a particularly expensive treatment, the difference can become enormous.

That is why foreign pharmacies have remained attractive despite the risks and legal uncertainty.

What happens next?

The immediate question is whether the new customs requirements will be implemented exactly as currently anticipated, whether additional guidance will change their practical impact, and whether regulators create accommodations for individual patients.

The broader question is harder.

If Americans are discouraged or prevented from relying on informal cross-border purchasing, what replaces it?

Formal importation programs could eventually provide one answer. Direct-to-consumer initiatives and other efforts to reduce domestic prices are another. The Department of Health and Human Services announced guidance in January 2026 intended to make it easier for drug manufacturers to offer certain lower-cost medicines directly to patients under specified safeguards. 

H

HHS.gov

But those programs do not necessarily solve the immediate problem for every patient.

For people already dependent on a foreign pharmacy, October is therefore more than a regulatory deadline. It is a test of whether the American health-care system can provide an affordable alternative when one of its unofficial escape valves begins to close.

The debate over Canadian prescriptions has never been simply about Canada.

It is ultimately about what happens when a medicine is affordable on one side of the border and unaffordable on the other—and what patients do when the border is no longer as easy to cross.